These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31254667)

  • 1. Semisynthetic bile acids: a new therapeutic option for metabolic syndrome.
    Lazarević S; Đanić M; Goločorbin-Kon S; Al-Salami H; Mikov M
    Pharmacol Res; 2019 Aug; 146():104333. PubMed ID: 31254667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
    Roda A; Pellicciari R; Gioiello A; Neri F; Camborata C; Passeri D; De Franco F; Spinozzi S; Colliva C; Adorini L; Montagnani M; Aldini R
    J Pharmacol Exp Ther; 2014 Jul; 350(1):56-68. PubMed ID: 24784847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights in the multiple roles of bile acids and their signaling pathways in metabolic control.
    de Boer JF; Bloks VW; Verkade E; Heiner-Fokkema MR; Kuipers F
    Curr Opin Lipidol; 2018 Jun; 29(3):194-202. PubMed ID: 29553998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
    Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
    Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
    Chiang JYL; Ferrell JM
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pharmacology of Bile Acids and Their Receptors.
    Fiorucci S; Distrutti E
    Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome.
    Ðanić M; Stanimirov B; Pavlović N; Goločorbin-Kon S; Al-Salami H; Stankov K; Mikov M
    Front Pharmacol; 2018; 9():1382. PubMed ID: 30559664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function.
    Comeglio P; Cellai I; Mello T; Filippi S; Maneschi E; Corcetto F; Corno C; Sarchielli E; Morelli A; Rapizzi E; Bani D; Guasti D; Vannelli GB; Galli A; Adorini L; Maggi M; Vignozzi L
    J Endocrinol; 2018 Aug; 238(2):107-127. PubMed ID: 29945982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
    Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
    Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acids, obesity, and the metabolic syndrome.
    Ma H; Patti ME
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):573-83. PubMed ID: 25194176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
    Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
    J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.
    Spinelli V; Chávez-Talavera O; Tailleux A; Staels B
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):138-44. PubMed ID: 26859552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation.
    Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A
    Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ENDOCRINOLOGY IN PREGNANCY: Metabolic impact of bile acids in gestation.
    Fan HM; Mitchell AL; Williamson C
    Eur J Endocrinol; 2021 Mar; 184(3):R69-R83. PubMed ID: 33434155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical exploration of TGR5 functional hot-spots: Synthesis and structure-activity relationships of C7- and C23-Substituted cholic acid derivatives.
    Rosatelli E; Carotti A; Cerra B; De Franco F; Passeri D; Pellicciari R; Gioiello A
    Eur J Med Chem; 2023 Dec; 261():115851. PubMed ID: 37813065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
    Brønden A; Knop FK
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
    Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
    Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FXR in cholestasis: hype or hope.
    Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
    Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.